mhurhangee/patent-ind-claim-en huggingface dataset:
Method for regulating a switching converter with quasi-resonant switching, wherein a PWM switching regulator is used to generate a PWM switching signal (PWM) with a variable clock frequency (f) and wherein a resonance signal (RES) is generated which specifies valleys (V1, V2, V3...Vn) of a voltage (U DS ) applied to a switching element and oscillating with a resonance frequency, characterised in that a PWM reference signal (REF) is formed, wherein its respective pulse duration (t REF ) is conversely proportional to the level of the clock frequency (f) or wherein a linear association with a dropping pulse duration (t REF ) exists when the frequency (f) is increasing, that in order to generate the PWM reference signal (REF), a control voltage (U STR ) which is directly proportional to the clock frequency (f) is superimposed onto a saw tooth signal (SIG) of the PWM switching regulator , that a control variable signal (REG) is derived from the PWM reference signal (REF), by its respective pulse duration (t φ ) being lengthened or shortened as a function of the resonance signal (RES) and that by changing the clock frequency (f) by means of a frequency regulator , the control variable signal (REG) is readjusted to the PWM reference signal (REF).
A method for dissecting and collecting one or more cells from a tissue sample (28, 28a-28n) fixed to a microfluidic device (20, 20a-20n), wherein said microfluidic device (20, 20a-20n) includes a channel (26, 26a-26n) having an inlet end (32, 32a-32n) and an outlet end (34, 34a-34n) for flowing fluid therethrough, and wherein said tissue sample (28, 28a-28n) is in fluid communication with said channel (26, 26a-26n), the method comprising: a) flowing a first fluid through the channel (26, 26a-26n) with a fluid flow from the inlet end (32, 32a-32n) to the outlet end (34, 34a-34n); b) communicating said tissue sample (28, 28a-28n) with said flowing first fluid ; c) powering a laser to direct laser energy into the channel (26, 26a-26n) to impinge upon the first fluid proximate a first region of the tissue sample (28, 28a-28n) at a distance from a surface of said tissue sample (28, 28a-28n), wherein said distance from said surface of said tissue sample is within about 100 nm to about 1 micron; d) causing fluid cavitation of said flowing first fluid to thereby hydrodynamically ablate a first set of one or more cells from the tissue sample (28, 28a-28n); e) capturing said ablated first set of one or more cells within said flowing first fluid for transporting to said outlet end (34, 34a-34n) of said channel (26, 26a-26n); and f) collecting the first set of one or more cells within a first sample container coupled to the outlet end (34, 34a-34n). a) flowing a first fluid through the channel (26, 26a-26n) with a fluid flow from the inlet end (32, 32a-32n) to the outlet end (34, 34a-34n); b) communicating said tissue sample (28, 28a-28n) with said flowing first fluid ; c) powering a laser to direct laser energy into the channel (26, 26a-26n) to impinge upon the first fluid proximate a first region of the tissue sample (28, 28a-28n) at a distance from a surface of said tissue sample (28, 28a-28n), wherein said distance from said surface of said tissue sample is within about 100 nm to about 1 micron; d) causing fluid cavitation of said flowing first fluid to thereby hydrodynamically ablate a first set of one or more cells from the tissue sample (28, 28a-28n); e) capturing said ablated first set of one or more cells within said flowing first fluid for transporting to said outlet end (34, 34a-34n) of said channel (26, 26a-26n); and f) collecting the first set of one or more cells within a first sample container coupled to the outlet end (34, 34a-34n).
A medical system comprising: a display console ; and a control computer connected to the display console, the control computer configured to: control each of a plurality of elements to measure temperature within an atrium of a heart and determine a location of each of one or more openings in the atrium inferred from the temperatures measured by the plurality of elements; establish a map of a plurality of ablation elements and the location of each of the one or more openings and cause the display console to display the map on the display console ; receive user-input indicating which elements of the plurality of ablation elements will cause tissue ablation in the atrium to define a user-selected ablation pattern; and cause, prior to beginning ablation of the user-selected ablation pattern in tissue, the display console to display a representation of the user-selected ablation pattern at least in response to the user-input. a display console ; and a control computer connected to the display console, the control computer configured to: control each of a plurality of elements to measure temperature within an atrium of a heart and determine a location of each of one or more openings in the atrium inferred from the temperatures measured by the plurality of elements; establish a map of a plurality of ablation elements and the location of each of the one or more openings and cause the display console to display the map on the display console ; receive user-input indicating which elements of the plurality of ablation elements will cause tissue ablation in the atrium to define a user-selected ablation pattern; and cause, prior to beginning ablation of the user-selected ablation pattern in tissue, the display console to display a representation of the user-selected ablation pattern at least in response to the user-input. control each of a plurality of elements to measure temperature within an atrium of a heart and determine a location of each of one or more openings in the atrium inferred from the temperatures measured by the plurality of elements; establish a map of a plurality of ablation elements and the location of each of the one or more openings and cause the display console to display the map on the display console ; receive user-input indicating which elements of the plurality of ablation elements will cause tissue ablation in the atrium to define a user-selected ablation pattern; and cause, prior to beginning ablation of the user-selected ablation pattern in tissue, the display console to display a representation of the user-selected ablation pattern at least in response to the user-input.
A system for providing ventilatory support, the system comprising: a gas source ; a gas delivery circuit (413; 2903; 3803); a nasal interface (303; 400; 501; 2405; 2801) that allows the patient to breathe ambient air through the nasal interface; a gas flow path (601; 903; 1615; 3101) through the nasal interface, wherein the gas flow path comprises a distal end gas flow path opening; a nozzle (611; 907; 1623; 2603; 2807; 3105) associated with a proximal end of the nasal interface at a distance from the distal end gas flow path opening, wherein the nozzle comprises a tip defining a minimum inner diameter of the nozzle; and an entrainment port associated with the nasal interface, wherein a portion of the entrainment port is between the tip of the nozzle and the distal end gas flow opening, wherein the tip of the nozzle is between a distal end and a proximal end of the entrainment port , wherein the nozzle (611; 907; 1623; 2603; 2807; 3105) is in fluid communication with the gas delivery circuit and the gas source, wherein the nasal interface (303; 400; 501; 2405; 2801) and the nozzle (611; 907; 1623; 2603; 2807; 3105) are configured so that when gas is delivered into the nasal interface through the nozzle, a positive pressure is created in an area between the entrainment port and the distal end gas flow path, and wherein a combination of gas from the gas source and air entrained through the entrainment port provide ventilatory support. a gas source ; a gas delivery circuit (413; 2903; 3803); a nasal interface (303; 400; 501; 2405; 2801) that allows the patient to breathe ambient air through the nasal interface; a gas flow path (601; 903; 1615; 3101) through the nasal interface, wherein the gas flow path comprises a distal end gas flow path opening; a nozzle (611; 907; 1623; 2603; 2807; 3105) associated with a proximal end of the nasal interface at a distance from the distal end gas flow path opening, wherein the nozzle comprises a tip defining a minimum inner diameter of the nozzle; and an entrainment port associated with the nasal interface, wherein a portion of the entrainment port is between the tip of the nozzle and the distal end gas flow opening, wherein the tip of the nozzle is between a distal end and a proximal end of the entrainment port , wherein the nozzle (611; 907; 1623; 2603; 2807; 3105) is in fluid communication with the gas delivery circuit and the gas source, wherein the nasal interface (303; 400; 501; 2405; 2801) and the nozzle (611; 907; 1623; 2603; 2807; 3105) are configured so that when gas is delivered into the nasal interface through the nozzle, a positive pressure is created in an area between the entrainment port and the distal end gas flow path, and wherein a combination of gas from the gas source and air entrained through the entrainment port provide ventilatory support.
An image display device comprising at least one point light source and at least one micro-display device in the form of a spatial light modulator being positioned to be illuminated by said at least one point light source , said spatial light modulator comprising a liquid crystal layer interposed between a top electrode and a two-dimensional array of pixels wherein each pixel is represented by a pixel electrode such that the liquid crystal layer is controlled through the array of pixel electrodes characterized in that; each pixel electrode is configured to have at least one optically active zone in the form of a reflective zone , a transmissive zone or a reflective coating , said optically active zones in the form of a reflective zone , a transmissive zone or a reflective coating only partially cover the surface of each pixel electrode and are configured to be located in a spaced-away positionment relative to each other and the ratio of the smallest dimension of an optically active zone to incident light wavelength is between 1 and 5 in the manner that light reflected or transmitted through neighbouring optically active zones in each pixel is diffracted to create an angular spread, wherein; said optically active zone is smaller than the pixel electrode , said optically active zone is delimited by an absorbing layer , said spatial light modulator is configured to display a phase only computer generated hologram and, said optically active zone's smallest dimension is at least 0.5 μm x 0.5 μm.
A device for obtaining mechanical, geometric, and dynamic measurements of optical surfaces characterized in that it comprises: - a high-speed stereoscopic imaging system ; - a spatially discrete stimulus generator configured for directing a spatially discrete stimulus to a first optical region and to a second optical region ; - a first projector configured for projecting a random infrared illumination pattern onto the entire surface of the second optical region ; - a second projector configured for projecting a slotted illumination pattern projected on the central area of the second optical region ; - a processor configured for calibrating the high-speed stereoscopic imaging system , calculating the position of the high-speed stereoscopic imaging system in space, establishing depth ratios in the high-speed stereoscopic imaging system , and determining the position of the second optical region in space and the depth ratio of the second optical region with respect to the high-speed stereoscopic imaging system ; wherein the high-speed stereoscopic imaging system is configured for obtaining at least one image of the random infrared illumination pattern projected onto the entire surface of the second optical region , as well as of the slotted illumination pattern projected onto the central area of the second optical region without the application of the spatially discrete stimulus , and also for obtaining images of the random infrared illumination pattern and of the slotted illumination pattern during and after the application of the spatially discrete stimulus which strikes the first optical region and the second optical region and propagates over the surface of the second optical region ; and wherein the processor is configured for generating a final image with three-dimensional information about the entire extension of the second optical region using a superposition, by means of digital image correlation, of the images obtained by means of the high-speed stereoscopic imaging system . - a high-speed stereoscopic imaging system ; - a spatially discrete stimulus generator configured for directing a spatially discrete stimulus to a first optical region and to a second optical region ; - a first projector configured for projecting a random infrared illumination pattern onto the entire surface of the second optical region ; - a second projector configured for projecting a slotted illumination pattern projected on the central area of the second optical region ; - a processor configured for calibrating the high-speed stereoscopic imaging system , calculating the position of the high-speed stereoscopic imaging system in space, establishing depth ratios in the high-speed stereoscopic imaging system , and determining the position of the second optical region in space and the depth ratio of the second optical region with respect to the high-speed stereoscopic imaging system ;
A bracket for mounting a vertical cable manager to a rack , the bracket configured to attach to a spine portion of the vertical cable manager having a recessed area and comprising: a first portion extending in a first direction, the first portion including an opening and a projecting element adjacent the opening; a second portion extending from the first portion in a second direction perpendicular to the first direction; and a third portion extending from the second portion in a third direction perpendicular to the second direction, parallel to the first direction and opposite to the first direction, wherein the first portion of the bracket is adapted to be snap-fitted to the vertical cable manager; and wherein the projecting element extends from the first portion on the same side as the second portion. a first portion extending in a first direction, the first portion including an opening and a projecting element adjacent the opening; a second portion extending from the first portion in a second direction perpendicular to the first direction; and a third portion extending from the second portion in a third direction perpendicular to the second direction, parallel to the first direction and opposite to the first direction, wherein the first portion of the bracket is adapted to be snap-fitted to the vertical cable manager; and wherein the projecting element extends from the first portion on the same side as the second portion.
Antiplatelet thrombolysin for use in the treatment of thrombotic thrombocytopenic purpura, wherein the antiplatelet thrombolysin consists of two polypetide chains: alpha chain and beta chain, the amino acid sequence of the alpha chain is shown as in SEQ ID NO.1, and the amino acid sequence of the beta chain is as shown in SEQ ID NO.2.
A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 is halogen or C 1 - 6 alkyl; R 2 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, or -CN; R 3 is hydrogen, halogen, or C 1-6 alkyl; R 4 is hydrogen, halogen, or C 1-6 alkyl; each R 5 is independently C 1-6 alkyl, -OH, or -NH 2 ; n is 0, 1, 2, or 3; and each of A 1 , A 2 , and A 3 is -CH- or -N-, where at least one of A 1 , A 2 , or A 3 is -N-for use in treating pancreatic cancer or in controlling an adenocarcinoma. R 1 is halogen or C 1 - 6 alkyl; R 2 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, or -CN; R 3 is hydrogen, halogen, or C 1-6 alkyl; R 4 is hydrogen, halogen, or C 1-6 alkyl; each R 5 is independently C 1-6 alkyl, -OH, or -NH 2 ; n is 0, 1, 2, or 3; and each of A 1 , A 2 , and A 3 is -CH- or -N-, where at least one of A 1 , A 2 , or A 3 is -N-for use in treating pancreatic cancer or in controlling an adenocarcinoma.
A geared motor having - an electric motor with an output shaft and - a gear mechanism , - the electric motor and the gear mechanism being adapted to one another in such a way that a bearing plate of the electric motor can be fastened directly to an input shaft side of a housing of the gear mechanism , and - a coupling thread which surrounds the output shaft for producing a threaded connection being provided for fastening the bearing plate to the input shaft side , characterized in that a securing section is provided which, in the fastened state, prevents a relative rotation of the housing of the gear mechanism with respect to the bearing plate in a release direction, said securing section being fastened to the bearing plate or to the gear mechanism housing by way of a fastening screw which is screwed into the bearing plate or the gear mechanism housing in a manner which is oriented in the tangential direction of the coupling thread . - an electric motor with an output shaft and - a gear mechanism , - the electric motor and the gear mechanism being adapted to one another in such a way that a bearing plate of the electric motor can be fastened directly to an input shaft side of a housing of the gear mechanism , and - a coupling thread which surrounds the output shaft for producing a threaded connection being provided for fastening the bearing plate to the input shaft side ,
A method for developing a diagnostic test for a particular disease, the method comprising the steps of: on a collected sample from each of multiple subjects in a patient group and a control group, wherein the patient group comprises subjects who have the same disease and the control group comprises subjects who are healthy; amplifying and sequencing the immune repertoire of each subject in each of the two groups to identify each unique CDR3 sequence present in the samples and to determine the frequency of occurrence of each unique CDR3 sequence; identifying CDR3 sequences that are shared between at least two subjects in each of the control group and the patient group; ranking the CDR3 sequences by order of frequency of occurrence; identifying the Linklets from each group; and identifying the Linklets that are associated to a statistically significant degree with the patient group to provide a disease signature. on a collected sample from each of multiple subjects in a patient group and a control group, wherein the patient group comprises subjects who have the same disease and the control group comprises subjects who are healthy; amplifying and sequencing the immune repertoire of each subject in each of the two groups to identify each unique CDR3 sequence present in the samples and to determine the frequency of occurrence of each unique CDR3 sequence; identifying CDR3 sequences that are shared between at least two subjects in each of the control group and the patient group; ranking the CDR3 sequences by order of frequency of occurrence; identifying the Linklets from each group; and identifying the Linklets that are associated to a statistically significant degree with the patient group to provide a disease signature.
A resource selection method for service data transmission, comprising: obtaining (S101), by a terminal, first configuration information, wherein the first configuration information comprises a first service feature parameter and a first resource parameter corresponding to the first service feature parameter; obtaining (S102), by the terminal, to-be-sent service data and a second service feature parameter corresponding to the to-be-sent service data; determining (S103), by the terminal based on the first service feature parameter, the second service feature parameter and the first resource parameter, a second resource parameter for transmitting the to-be-sent service data, wherein the first resource parameter and the second resource parameter each comprise a first time parameter or a value range parameter of a first time parameter; selecting (SI04), by the terminal based on the second resource parameter, an available resource for transmitting the to-be-sent service data; and transmitting (S105), by the terminal, the to-be-sent service data by using the available resource. obtaining (S101), by a terminal, first configuration information, wherein the first configuration information comprises a first service feature parameter and a first resource parameter corresponding to the first service feature parameter; obtaining (S102), by the terminal, to-be-sent service data and a second service feature parameter corresponding to the to-be-sent service data; determining (S103), by the terminal based on the first service feature parameter, the second service feature parameter and the first resource parameter, a second resource parameter for transmitting the to-be-sent service data, wherein the first resource parameter and the second resource parameter each comprise a first time parameter or a value range parameter of a first time parameter; selecting (SI04), by the terminal based on the second resource parameter, an available resource for transmitting the to-be-sent service data; and transmitting (S105), by the terminal, the to-be-sent service data by using the available resource.
A compound for use in treating cancer selected from the following table: Cmpd. No. Structure Compound Name 28 2-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)-1-phenylpropan-1-one 77 2-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)-1-(4-fluorophenyl)propan-1-one 78 2-((5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)thio)-1-(2,5-difluorophenyl)propan-1-one 79 1-(3-chlorophenyl)-2-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)propan-1-one 80 1-(2,5-difluorophenyl)-2-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)propan-1-one 81 2-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)-1-(3-fluorophenyl)propan-1-one 85 N-(1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)benzenesulfonamide 86 3-{[5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl}-1-phenylpropan-1-ol 87 1-{[5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl} -3-phenylpropan-2-ol 88 3-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)-4-phenylbutan-2-one 89 2-f [5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl}-1-phenylethan-1-ol 90 1-((5-(4-ethylphenyl)-4H-1,2,4-triazol-3-yl)thio)-3-phenylpropan-2-one 91 3-(4-ethylphenyl)-5-((2-phenylcyclopropyl)thio)-4H-1,2,4-triazole 92 1-(3-fluorophenyl)-2-{[5-(4-methox yphenyl)-1H-1,2,4-triazol-3-yl]sulfa nyl}propan-1-one 93 2-{[5-(5-ethylpyridin-2-yl)-1H-1,2,4 -triazol-3-yl]sulfanyl}-1-phenylprop an-1-one 94 2-{[5-(4-ethylphenyl)-1H-1,2,4-triaz ol-3-yl]sulfanyl}-1-(pyridin-2-yl)pro pan-1-one 95 2-{[5-(5-ethylpyridin-2-yl)-1H-1,2,4 -triazol-3-yl]sulfanyl}-1-(pyridin-2-yl)propan-1-one 96 1-(3-fluorophenyl)-2-{[5-(4-methan esulfonylphenyl)-1H-1,2,4-triazol-3-yl]sulfanyl}propan-1-one 97 1-(3-fluorophenyl)-2-{[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]sulfanyl}pr opan-1-one 98 1-(4-ethylphenyl)-2-{[5-(pyridin-4-y l)-1H-1,2,4-triazol-3-yl]sulfanyl}pro pan-1-one 99 2-{[5-(4-ethylphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-1-(3-fluo rophenyl)propan-1-one 100 2-{[5-(4-ethylphenyl)-4H-1,2,4-triaz ol-3-yl]sulfonyl}-1-(3-fluorophenyl) propan-1-one 101 2-{[5-(4-ethylphenyl)-4H-1,2,4-triaz ol-3-yl]sulfanyl}-1-(3-fluorophenyl) propan-1-one 102 2-{[5-(4-ethylphenyl)-4H-1,2,4-triaz ol-3-yl]sulfanyl}-1-(3-nitrophenyl)p ropan-1-one 103 1-(3-aminophenyl)-2-{[5-(4-ethylph enyl)-4H-1 ,2,4-triazol-3-yl]sulfanyl} propan-1-one 104 N-[3-(2-{[5-(4-ethylphenyl)-4-meth anesulfonyl-4H-1,2,4-triazol-3-yl]su lfanyl} propanoyl)phenyl] methanesulfonamide 105 N-[3-(2-{[5-(4-ethylphenyl)-4H-1,2, 4-triazol-3-yl]sulfanyl}propanoyl)ph enyl] methanesulfonamide 106 2-{[5-(6-ethylpyridin-3-yl)-4H-1,2,4 -triazol-3-yl]sulfanyl}-1-(3-fluoroph enyl)propan-1-one